Overview

DAPPAR AF Dabigatran for Peri Procedural Anticoagulation During Radiofrequency Ablation of Atrial Fibrillation

Status:
Completed
Trial end date:
2017-06-07
Target enrollment:
Participant gender:
Summary
It is hypothesized that peri-ablation Dabigatran will be a safe and effective method of peri-procedural anticoagulation for Atrial Fibrillation (AF) ablation, resulting in a low rate of peri-procedural bleeding and thromboembolic complications.
Phase:
Phase 4
Details
Lead Sponsor:
Allan Skanes
Lawson Health Research Institute
Collaborator:
Boehringer Ingelheim
Treatments:
Dabigatran